Home » Stocks » IPHA

Innate Pharma S.A. (IPHA)

Stock Price: $4.44 USD -0.15 (-3.27%)
Updated Jan 15, 2021 11:52 AM EST - Market open
Market Cap 352.17M
Revenue (ttm) 96.42M
Net Income (ttm) -23.32M
Shares Out 74.71M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $4.44
Previous Close $4.59
Change ($) -0.15
Change (%) -3.27%
Day's Open 4.60
Day's Range 4.44 - 4.59
Day's Volume 659
52-Week Range 3.77 - 8.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

MARSEILLE, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made ...

GlobeNewsWire - 1 week ago

Marseille, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that Sanofi has made the deci...

GlobeNewsWire - 1 week ago

MARSEILLE, France, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its s...

GlobeNewsWire - 1 week ago

Marseille, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior ma...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - December 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate"...

GlobeNewsWire - 3 weeks ago

Investors with losses are encouraged to contact the firm before December 22, 2020; click here to submit trade information Investors with losses are encouraged to contact the firm before Decemb...

PRNewsWire - 3 weeks ago

LOS ANGELES, Dec. 21, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Innate Pharma S.A. ("Innat...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - December 21, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...

Business Wire - 3 weeks ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA...

Newsfile Corp - 3 weeks ago

New York, New York--(Newsfile Corp. - December 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...

Business Wire - 3 weeks ago

NEW YORK--(BUSINESS WIRE)-- #classaction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the ...

Business Wire - 4 weeks ago

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class ...

PRNewsWire - 4 weeks ago

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and ...

PRNewsWire - 1 month ago

BENSALEM, Pa., Dec. 14, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action fil...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA).   Such investors are ...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Innate Pharma S.A. (NASDAQ: IPHA) between March 1...

GlobeNewsWire - 1 month ago

MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return t...

GlobeNewsWire - 1 month ago

Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US an...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 9, 2020) -   Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between...

GlobeNewsWire - 1 month ago

LOS ANGELES, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class act...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: I...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are ad...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - December 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...

GlobeNewsWire - 1 month ago

Phase 2 expansion cohort data supports ongoing Phase 3 trial Phase 2 expansion cohort data supports ongoing Phase 3 trial

PRNewsWire - 1 month ago

NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA). Such investors are advised...

GlobeNewsWire - 1 month ago

MARSEILLE, France, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial cal...

PRNewsWire - 1 month ago

NEW YORK, Dec. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and S...

GlobeNewsWire - 1 month ago

LOS ANGELES, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class act...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Innate Pharma S.A. (NASDAQ: I...

Newsfile Corp - 1 month ago

New York, New York--(Newsfile Corp. - November 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...

GlobeNewsWire - 1 month ago

Marseille, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash positio...

PRNewsWire - 2 months ago

NEW YORK, Nov. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and ...

GlobeNewsWire - 2 months ago

Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Priority Medicines (PRIME) designation supports...

GlobeNewsWire - 2 months ago

MARSEILLE, France, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that members of its ...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 9, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 7, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between ...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 6, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" ...

Business Wire - 2 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma...

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA...

PRNewsWire - 2 months ago

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and ...

Business Wire - 2 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Innate Pharma SA (IPHA) Inv...

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or o...

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray, Leading Securities Fraud Law Firm, Announces Filing of Securities Class Action on Behalf of Innate Pharma SA (IPHA...

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #classaction--The Law Offices of Frank R. Cruz announces an investigation of Innate Pharma SA (“Innate” or the “Company”) (NASDAQ: IPHA) on behalf of inv...

Business Wire - 2 months ago

BENSALEM, Pa.--(BUSINESS WIRE)---- $IPHA #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Innate Pharma SA (IPHA) on Behalf of Investors

Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)---- $IPHA #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Innate Pharma SA (IPHA) on Behalf of Investors

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between March 10, 2020 and September 8, ...

PRNewsWire - 2 months ago

SAN DIEGO and MARSEILLE, France, Oct. 27, 2020 /PRNewswire/ -- Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Innate Pharma S.A...

PRNewsWire - 2 months ago

NEW YORK, Oct. 26, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA). Such investors are advise...

About IPHA

Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the trea... [Read more...]

Industry
Biotechnology
IPO Date
Oct 17, 2019
CEO
Mondher Mahjoubi
Employees
247
Stock Exchange
NASDAQ
Ticker Symbol
IPHA
Full Company Profile

Financial Performance

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Innate Pharma stock is "Buy." The 12-month stock price forecast is 6.31, which is an increase of 42.12% from the latest price.

Price Target
$6.31
(42.12% upside)
Analyst Consensus: Buy